Syngenta to Establish £100m Agricultural Bioscience Centre in Berkshire
Syngenta, a leading global agrichemical company owned by China National Chemical Corporation, is set to develop a new £100 million research centre dedicated to agricultural bioscience. The facility will be located at the company’s Jealott’s Hill site in Berkshire and is expected to accommodate hundreds of scientists. This initiative has been described by the UK government as a clear endorsement of the country’s scientific capabilities.
The announcement marks a positive development in the relationship between the research sector and government, following tensions with the pharmaceutical industry over drug pricing and related matters that led to a public dispute last year.
Focus and Features of the New Bioscience Hub
The forthcoming centre, named BioSTaR (Biological Sciences Technology and Research), will consolidate Syngenta’s bioscience operations into a single location, bringing together approximately 300 scientists. The hub will concentrate on advancing technologies such as biological pesticides, which represent the next generation of crop protection solutions. Additionally, there will be significant investment in artificial intelligence tools to support and enhance research activities.
Currently, Syngenta employs around 800 people at Jealott’s Hill, its largest research and development site globally, working in areas including global product safety, digital imaging, and discovery chemistry. Across the UK, the company has a workforce exceeding 2,000 employees spread over six sites. No new jobs are planned during the initial phase of the BioSTaR project.
Government Support and Industry Context
Angela Eagle, the UK farming minister, commented on the investment:
“This is a clear vote of confidence in the UK and our world-leading agricultural science.”
She further noted that the government is allocating £345 million in grants aimed at supporting equipment and innovation to assist farmers in adopting more sustainable food production methods.
Company Background and Market Developments
Syngenta was established in 2000 through the merger of the agrichemical divisions of Novartis and AstraZeneca and is listed on the New York Stock Exchange. In 2017, it was acquired by China National Chemical Corporation. The company reported sales of approximately £23 billion ($30 billion) for the year 2024.
Reports indicate that Syngenta is considering a significant initial public offering (IPO) in Hong Kong, aiming to raise up to £7.5 billion ($10 billion) by floating 20% of the company. Syngenta has declined to comment on these IPO plans.
Project Timeline and Research Objectives
The new BioSTaR centre is anticipated to be completed by 2028. Research efforts will encompass designing sustainable crop protection products that employ novel chemical and biological modes of action. The centre will also focus on anticipating resistance development in crops and creating products responsive to environmental factors such as temperature and soil quality.
Camilla Corsi, global head of crop protection research and development at Syngenta, stated:
“We are focused on creating a more productive and sustainable future for agriculture. With this investment, we are pushing the boundaries of science.”
Recent Company Announcements
Earlier in the month, Syngenta announced its decision to cease production of paraquat, a herbicide manufactured exclusively at its Huddersfield factory, by the end of June. The company cited competition from generic producers as the reason for this move. This decision comes amid ongoing legal claims from former users who allege they developed Parkinson’s disease due to exposure to paraquat.
